Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

    ... to intense investigation. For SF3b1, a gain of function mutation may offer the promise of new targeted therapies for diseases that ...

    Research Article last updated 07/31/2012 - 2:06pm.

  2. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

    ... (VAFs) for founding clone mutations. At least one mutation or cytogenetic abnormality was detected in 83% of the 150 MDS ...

    Research Article last updated 03/05/2013 - 8:30am.

  3. Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

    ... 1.85 to 4.52). CONCLUSION Combining the LR-PSS and EZH2 mutation status identifies 29% of patients with lower-risk MDS with a ...

    Research Article last updated 10/01/2012 - 10:09am.

  4. MDS Rounds: An AAMDSIF Visiting Faculty Program

    ... relationship between clinical symptoms and genetic mutation profiles. •    During the past decade, extensive research ...

    Page last updated 11/18/2016 - 12:55pm.

  5. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... intermediate-risk MDS settings and a specific genetic mutation (deletion in the long arm of chromosome 5, abbreviated as del(5q). ... no longer used to treat MDS due to its side effects. The mutation of del(5q) is important as it likely deletes genes that are important ...

    Research Review last updated 05/02/2016 - 9:12am.

  6. Interviews with the Experts: Hemolysis in PNH and Beyond

    ... proteins.  What happens in PNH is that an acquired mutation in a gene ( PIG-A gene ) in hematopoietic stem cells ...

    Interview last updated 08/31/2016 - 8:40am.

  7. AA&MDSIF announces PNH grant awards

    ... aplastic anemia . PNH is caused by a somatic mutation in the PIG-A gene , which is responsible for a cellular ... will be used to examine the functional effects of the PIG-A mutation in CD34+ cells and T- cells shared by PNH, MDS and aplastic anemia ...

    Article last updated 12/14/2016 - 11:41am.

  8. Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

    ... evaluate 1 dose level of AG-120 in patients with an IDH1 mutation and 2 dose levels of AG-221 in patients with an IDH2 mutation. AG-120 or AG-221 will be administered with 2 types of AML induction ...

    Clinical Trial last updated 04/28/2016 - 4:16pm.

  9. Dr. Vivienne Rebel reviews a recent study about p53 protein levels as a prognostic factor in MDS

    ... have shown that if the 5q deletion is accompanied by a mutation in the p53 gene (the official name of this gene in TP53), there is ... risk was clear even if the number of cells showing this mutation was relatively small.  The method currently used to identify p53 ...

    Research Review last updated 05/02/2016 - 9:17am.

  10. Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

    ... in patients with AML and high risk MDS with FLT3-ITD mutation . The safety of this drug combination will also be studied. ...

    Clinical Trial last updated 04/29/2016 - 12:23pm.